---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-016752"
form_type: "8-K"
ticker: "KALA"
cik: "0001479419"
company_name: "KALA BIO, Inc."
filed_at: "2022-11-08T23:59:59+00:00"
generated_at: "2026-06-22T03:22:20.218885+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Kala Pharma reports $52.4M cash; plans Phase 2/3 trial for KPI-012 in Q4 2022 with data 1Q 2024

## Summary
- Cash and equivalents of $52.4M as of Sept 30, 2022, expected to fund operations into Q2 2024.
- Plans to initiate Phase 2/3 trial of KPI-012 for PCED in Q4 2022; topline data expected Q1 2024.
- Appointed Marjan Farid, M.D., to Board of Directors in November 2022.
- Effected 1-for-50 reverse stock split on October 20, 2022.

## SEC filing metadata
- accession: 0001558370-22-016752
- form_type: 8-K
- ticker: KALA
- cik: 0001479419
- company_name: KALA BIO, Inc.
- filed_at: 2022-11-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479419/000155837022016752/0001558370-22-016752-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479419/000155837022016752/kala-20221108x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-016752
- JSON: https://secwatch.observer/filing/0001558370-22-016752.json
- Plain text: https://secwatch.observer/filing/0001558370-22-016752.txt

## Key facts
- Earnings Releases
  KALA BIO, Inc. reported financial results for the third quarter ended September 30, 2022.
  - Period: the third quarter ended September 30, 2022
  - Result: reported results
  source text: On November 8, 2022, Kala Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479419/000155837022016752/0001558370-22-016752-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.